The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach ...

Marker Therapeutics (NASDAQ:MRKR) shares popped 11% Tuesday morning after the immuno-oncology company won a $9.5M grant from ...

Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat ...

The researchers found that administering 75 grams of vitamin C three times a week doubled overall survival rates of patients ...

The Center for Metastasis Research eXcellence (MET-X) is an interdisciplinary and collaborative program at Fred Hutchinson Cancer Center focused on one of the most challenging areas of cancer biology: ...

The FDA advised that the on-going VIRAGE Phase 2b study should not be expanded into a Phase 3 study; rather, the optimal path forward for the VCN-01 PDAC program is to conduct a stand-alone Phase 3 ...

the sudden rise in pancreatic cancer incidence is largely being driven by another type of tumor — endocrine cancers. They tend to be indolent, taking years or even decades to grow and spread ...

"Our collaboration would like to see if we can administer these agents to pancreatic cancer patients or other patients that develop peritoneal metastasis, which is often associated with cancer ...